MedPath

Serum Amyloid A Protein And Fetuin A Levels

Completed
Conditions
Periodontal Diseases
Interventions
Biological: Fetuin-A
Biological: Serum Amyloid A
Registration Number
NCT02433405
Lead Sponsor
Bulent Ecevit University
Brief Summary

The purpose of this study was to evaluate acute phase proteins (APPs) Fetuin-A and Serum Amyloid A (SAA) levels in gingival crevicular fluid (GCF) and serum samples in periodontal health and disease.

Detailed Description

The study population consisted totally 60 subjects consulted to Bulent Ecevit University, Faculty of Dentistry, Department of Periodontology whose age and sex were matched.

According to study design, subjects were divided into three groups based on their periodontal parameters. Patients suffering from chronic periodontitis formed the group 1 (n: 20), patients with plaque induced gingivitis formed the group 2 (n:20) and periodontal healthy patients were inserted in group 3 (n:20).

After gently drying the area, GCF was sampled with filter paper using the intracrevicular method (Periopaper, ProFlow, Inc., Amityville, New York, USA).Two milliliters (ml) of peripheral blood was collected from each individual with sterile syringe from the antecubital fossa by venipuncture, and to separate serum component sample centrifuged at 3000g for 5 min, and immediately stored at -40°C until assayed.

The quantity of Fetuin-A and SAA protein concentration in the samples were analyzed by sandwich enzyme-linked immunosorbent assay (ELISA) procedures using commercially available kits.

The Spearman's rank correlation test was used to detect the relationship between GCF and serum SAA and Fetuin-A with GI and CAL. All tests were performed using statistical software (SPSS Inc., version 22.0, Chicago, IL, USA). The mean ± standard deviation with mean rank values were calculated for each parameter, based on the patients as the statistical unit. P \< 0.05 was considered to be statistically significant.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria
  • GI>1, PPD≥5mm, CAL≥5mm with alveolar bone loss radiographically.
  • Systematically healthy patients

Group 2 Inclusion Criteria:

  • No alveolar bone and attachment loss
  • Inflammation signs such as redness, edema and increased BOP levels,
  • GI≥2, PPD≤3mm, CAL≤3mm.
  • Systematically healthy patients

Group 3 Inclusion Criteria:

  • No bone and attachment loss,
  • GI=0, PPD≤3mm, CAL≤3mm
  • Systematically healthy patients

Exclusion Criteria for all groups:

  • Aggressive Periodontitis,
  • Oral pathologies,
  • Patients with any other systemic diseases,
  • Pregnant women and those in the lactation period,
  • Patients with smoking habit and taking medication
  • Patients received periodontal therapy in last 6 months
Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Group 1Fetuin-AChronic Periodontitis-serum amyloid A, Fetuin-A
Group 3Serum Amyloid AControl Group-serum amyloid A, Fetuin-A
Group 1Serum Amyloid AChronic Periodontitis-serum amyloid A, Fetuin-A
Group 2Fetuin-APlaque induced Gingivitis-serum amyloid A, Fetuin-A
Group 2Serum Amyloid APlaque induced Gingivitis-serum amyloid A, Fetuin-A
Group 3Fetuin-AControl Group-serum amyloid A, Fetuin-A
Primary Outcome Measures
NameTimeMethod
Serum Amyloid A (SAA) levels as an inflammatory marker in periodontal disease both in serum and GCFDay 0
Secondary Outcome Measures
NameTimeMethod
Fetuin-A levels as an inflammatory marker in periodontal disease both in serum and GCFDay 0
© Copyright 2025. All Rights Reserved by MedPath